Systemic treatments for cutaneous T‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, observational analysis of adult patients with confirmed cutaneous T‑cell lymphoma who received a systemic therapy for at least three months between January 1, 2016 and December 31, 2023. Investigators will collect complete medical records from participating Italian centers to describe which systemic agents and treatment sequences were used, duration of responses, and treatment-related adverse events in real‑world practice. No experimental interventions are given; the study analyzes existing clinical care under EORTC 2017 diagnostic criteria. The goal is to map contemporary treatment patterns and outcomes where randomized evidence is limited, informing clinicians and future research priorities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1.
* Age ≥18 years.
* Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2023.
* Availability of complete medical records in order to provide protocol required variables
* Signed written informed consent.

Exclusion Criteria:

* Patients not meeting the above-mentioned inclusion criteria.
* Refuse to sign a written informed consent.

Where it's running

• AOU Ospedali Riuniti delle Marche - Clinica di Ematologia
  Ancona, Italy Recruiting
• IRCCS Istituto Tumori Giovanni Paolo II - U.O.C. Ematologia
  Bari, Italy Recruiting
• Policlinico S.Orsola-Malpighi - Istituto di Ematologia
  Bologna, Italy Recruiting
• Unità funzionale di Ematologia - Azienda Ospedaliera Universitaria Careggi
  Florence, Italy Recruiting
• S.C. Dermatologia - E.O. Galliera
  Genova, Italy Recruiting
• U.O.C. Dermatologia - Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Pietro Quaglino, MD — SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino
• Study coordinator: Uffici Studi FIL
• Email: startup@filinf.it
• Phone: +390131033153

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Molecular subtyping for treating cutaneous T-cell lymphoma

  This study is testing if personalized treatment plans based on specific molecular types can help people with cutaneous T-cell lymphoma feel better and live longer.

  Recruiting at 3 sites Peking University First Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06436677

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Ropeginterferon treatment for cutaneous T‑cell lymphoma

  This trial tests whether ropeginterferon-alfa-2b helps people with cutaneous T‑cell lymphoma who have not responded adequately to multiple prior skin-directed therapies.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT07047885

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Tofacitinib cream for treating early-stage Cutaneous T-cell Lymphoma

  This study is testing if a new cream can help people with early-stage Cutaneous T-cell Lymphoma feel better and improve their skin after 12 weeks of treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06698822

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.